These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 20368574)

  • 21. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
    Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
    J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of different ovarian cancer detection algorithms.
    Macuks R; Baidekalna I; Donina S
    Eur J Gynaecol Oncol; 2011; 32(4):408-10. PubMed ID: 21941963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
    Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
    Moore RG; McMeekin DS; Brown AK; DiSilvestro P; Miller MC; Allard WJ; Gajewski W; Kurman R; Bast RC; Skates SJ
    Gynecol Oncol; 2009 Jan; 112(1):40-6. PubMed ID: 18851871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.
    Shadfan BH; Simmons AR; Simmons GW; Ho A; Wong J; Lu KH; Bast RC; McDevitt JT
    Cancer Prev Res (Phila); 2015 Jan; 8(1):37-48. PubMed ID: 25388014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Designing early detection programs for ovarian cancer.
    Hartge P
    J Natl Cancer Inst; 2010 Jan; 102(1):3-4. PubMed ID: 20042718
    [No Abstract]   [Full Text] [Related]  

  • 34. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
    Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
    Urban N; Thorpe JD; Bergan LA; Forrest RM; Kampani AV; Scholler N; O'Briant KC; Anderson GL; Cramer DW; Berg CD; McIntosh MW; Hartge P; Drescher CW
    J Natl Cancer Inst; 2011 Nov; 103(21):1630-4. PubMed ID: 21917606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HE4 as a biomarker for ovarian and endometrial cancer management.
    Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
    Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.
    Moore RG; Jabre-Raughley M; Brown AK; Robison KM; Miller MC; Allard WJ; Kurman RJ; Bast RC; Skates SJ
    Am J Obstet Gynecol; 2010 Sep; 203(3):228.e1-6. PubMed ID: 20471625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HE4: a new potential early biomarker for the recurrence of ovarian cancer.
    Anastasi E; Marchei GG; Viggiani V; Gennarini G; Frati L; Reale MG
    Tumour Biol; 2010 Apr; 31(2):113-9. PubMed ID: 20358424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
    Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
    Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum biomarker panels for the detection of pancreatic cancer.
    Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
    Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.